XNW27011 is an anti‑CLDN18.2 ADC. It binds CLDN18.2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that causes DNA damage. Topoisomerase I is not the recognized surface target; cells are only killed if they express CLDN18.2, not merely Topo I.